# Regorafenib (Stivarga)

Source: https://ourhealthnetwork.com/drugs/regorafenib
Data: FDA Orange Book and OpenFDA, refreshed periodically

## What is Regorafenib?

Regorafenib (brand name: Stivarga) is a kinase inhibitor. It is prescribed to treat carcinoma, hepatocellular, colorectal neoplasms.

## Brand names

Stivarga

## Indications

Regorafenib is prescribed for several conditions including carcinoma, hepatocellular, colorectal neoplasms, among others.

## Conditions treated

- [Carcinoma](https://ourhealthnetwork.com/conditions/carcinoma)
- [Hepatocellular](https://ourhealthnetwork.com/conditions/hepatocellular)
- [Colorectal Neoplasms](https://ourhealthnetwork.com/conditions/colorectal-neoplasms)
- [Gastrointestinal Stromal Tumors](https://ourhealthnetwork.com/conditions/gastrointestinal-stromal-tumors)

## Mechanism of action

Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions and in pathologic processes such as oncogenesis, tumor angiogenesis, metastasis and tumor immunity. In in vitro biochemical or cellular assays, regorafenib or its major human active metabolites M-2 and M-5 inhibited the activity of RET, VEGFR1, VEGFR2, VEGFR3, KIT, P

## Drug classification

- Established Pharmacologic Class: kinase inhibitors
- Route of administration: ORAL

## Common side effects

asthenia/fatigue, decreased appetite/food intake, diarrhea, dysphonia, fever, hfsr, hyperbilirubinemia, hypertension

## Sources and disclaimers

- FDA Orange Book and OpenFDA dataset
- This information is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional before starting, stopping, or changing any medication.

## Related

- [All drugs](https://ourhealthnetwork.com/drugs)
- [Find specialists who prescribe this drug](https://ourhealthnetwork.com/find-doctors)
- [Methodology](https://ourhealthnetwork.com/methodology)